NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sol-Gel Technologies Ltd. (SLGL) Stock Analysis

Sol-Gel Technologies Ltd. (SLGL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SLGL

$69.52

−$0.58 (−0.83%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLGL with… →

SLGL Key Statistics

As of Sep 4, 2026
Trading
Open
$70.17
Previous Close
$70.10
Day's Range
68.39–70.80
52-Week Range
23.13–97.97
Volume
29.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.13
Valuation
Market Cap
$227.61M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
126.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.62
Financials (FY)
Revenue (FY)
$19.39M+68.04%
Net Income (FY)
−$6.13M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.27M
1-Year Return
+148.29%
Dividend and dates
Earnings Date
November 19, 2026estimated
Avg Volume
51.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLGL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+64.97%
2025+353.12%
2024−15.84%
2023−75.77%
2022−38.38%
2021−24.41%
2020−42.92%
2019+184.88%
2018 (partial year)−55.87%

As of September 4, 2026.

SLGL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$19.39M−$6.13M−31.6%
2024$11.54M−$10.58M−91.7%
2023$1.55M−$27.24M−1752.8%
2022$3.88M−$14.92M−384.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$19.39M—−$7.54M−$6.13M−31.6%
2024$11.54M—−$12.01M−$10.58M−91.7%
2023$1.55M—−$29.31M−$27.24M−1752.8%
2022$3.88M—−$16.24M−$14.92M−384.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SLGL Valuation vs Biotechnology Median

Median of 656 stocks
MetricSLGLBiotechnology medianvs median
P/S ratio126.8015.268.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sol-Gel Technologies Ltd. (SLGL) carries a market capitalisation of $227.61M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

The most recent close on file for SLGL is $69.52, dated September 4, 2026. That is −$0.58 (−0.83%) against the previous close. Over the past 52 weeks the price has ranged from $23.13 to $97.97. The latest close sits 200.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $19.39M. That is +68.04% against the prior fiscal year, when revenue was $11.54M. The same year closed with a net loss of $6.13M. Profit margin runs at 0%. Trailing earnings per share are −5.62.

Across the 4 fiscal years on file, revenue moves from $3.88M in 2022 to $19.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 126.8 times revenue. On price-to-sales that is 8.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.13. Daily returns over the trailing 8 years annualize to a volatility of 134.77%. The trailing one-year price return is +148.29%. Across 5 years the annualized return works out at −7.48%.

Growth & Income

No dividend is on file for SLGL.

2026 is still running; the price is +64.97% year to date. Across the complete calendar years on file, 2025 returned +353.12% and 2023 returned −75.77%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Sol-Gel Technologies Ltd. (SLGL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sol-Gel Technologies Ltd. SLGL $227.61M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sol-Gel Technologies Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Visit website →